- ISIN
- US45258J1025
- CUSIP
- 45258J102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 21, 2019
Highlights
- Market Cap
- $7.76B
- Enterprise Value
- $6.86B
- EPS (TTM)
- -$2.77
- Gross Profit (TTM)
- -$206.00K
- EBITDA (TTM)
- -$527.21M
- Year Range
- $14.32 - $38.74
- Target Price
- $43.67
- ROA (TTM)
- -52.83%
- ROE (TTM)
- -59.30%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
IMVT Performance Chart
Immunovant, Inc. (IMVT) is up 49.9% since the beginning of the year. At $38 per share, IMVT is trading just below its 52-week high of $39. Investors who bought $1,000 worth of IMVT shares 5 years ago would now be looking at an investment worth $3,464.
Loading charts...
Returns By Period
Immunovant, Inc. (IMVT) has returned 49.88% so far this year and 141.14% over the past 12 months.
Immunovant, Inc.
- 1D
- 7.81%
- 1M
- 11.57%
- YTD
- 49.88%
- 6M
- 38.34%
- 1Y
- 141.14%
- 3Y*
- 24.11%
- 5Y*
- 28.21%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
IMVT Monthly Returns History
Based on dividend-adjusted daily data since Dec 19, 2019, IMVT's average daily return is +0.17%, while the average monthly return is +3.27%. At this rate, an investment would double in approximately 1.8 years.
Historically, 47% of months were positive and 53% were negative. The best month was Oct 2022 with a return of +100.7%, while the worst month was Feb 2021 at -59.6%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 7 months.
On a daily basis, IMVT closed higher 49% of trading days. The best single day was Sep 26, 2023 with a return of +97.0%, while the worst single day was Feb 2, 2021 at -42.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.28% | 6.65% | -10.42% | 9.28% | 22.67% | 14.41% | 49.88% | ||||||
| 2025 | -12.23% | -5.24% | -17.04% | -5.50% | -8.05% | 7.74% | 0.50% | -8.64% | 9.73% | 53.10% | -2.15% | 5.26% | 2.62% |
| 2024 | -13.58% | -2.86% | -8.65% | -15.07% | -7.47% | 3.98% | 10.11% | 6.30% | -7.73% | 2.63% | -3.62% | -12.16% | -41.21% |
| 2023 | 0.11% | -1.69% | -11.22% | 4.06% | 30.17% | -9.71% | 20.35% | -0.53% | 69.04% | -13.91% | 18.40% | 7.67% | 137.35% |
| 2022 | -17.96% | -20.17% | -1.25% | -16.33% | -8.03% | -8.02% | 5.64% | 25.00% | 8.35% | 100.72% | 17.05% | 35.39% | 108.33% |
| 2021 | -15.50% | -59.57% | 1.65% | -2.24% | -3.32% | -30.28% | -1.04% | -17.21% | 0.35% | -7.48% | -4.23% | 10.65% | -81.55% |
Benchmark Metrics
Immunovant, Inc. has an annualized alpha of 33.26%, beta of 0.99, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since December 19, 2019.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (48.67%) than losses (13.28%) - typical of diversified or defensive assets.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 33.26%
- Beta
- 0.99
- R²
- 0.07
- Upside Capture
- 48.67%
- Downside Capture
- 13.28%
Return for Risk
Risk / Return Rank
IMVT ranks 92 for risk / return — in the top 92% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Immunovant, Inc. (IMVT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IMVT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.23 | ||
| Sortino ratioReturn per unit of downside risk | +0.78 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.37 | +0.02 |
| Calmar ratioReturn relative to maximum drawdown | 6.77 | 2.78 | +3.98 |
| Martin ratioReturn relative to average drawdown | 15.48 | 12.44 | +3.05 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Immunovant, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Immunovant, Inc. was 93.59%, occurring on Jun 16, 2022. The portfolio has not yet recovered.
The current Immunovant, Inc. drawdown is 27.72%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -93.59%Jun 2022 | 1y 7mo | — | 5y 7moNov 2020 - now |
COVID crash2020 | -51.20%Mar 2020 | 2mo 1d | 27d | 2mo 28dJan 2020 - Apr 2020 |
2020 bear market2020 | -20.50%Jul 2020 | 1mo 7d | 19d | 1mo 26dJun 2020 - Aug 2020 |
2020 correction2020 | -17.39%May 2020 | 7d | 7d | 14dMay 2020 - May 2020 |
2020 correction2020 | -13.21%Sep 2020 | 6d | 15d | 21dSep 2020 - Oct 2020 |
Drawdown Indicators
| IMVT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.59% | -56.78% | -36.81% |
Max Drawdown (1Y)Largest decline over 1 year | -20.98% | -9.10% | -11.88% |
Max Drawdown (3Y)Largest decline over 3 years | -69.88% | -18.90% | -50.98% |
Max Drawdown (5Y)Largest decline over 5 years | -70.38% | -25.43% | -44.95% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -27.72% | -1.80% | -25.92% |
Average DrawdownAverage peak-to-trough decline | -53.85% | -10.71% | -43.14% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.15% | 2.03% | +7.12% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Immunovant, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Immunovant, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for IMVT in comparison with other companies in the Biotechnology industry. Currently, IMVT has a P/B value of 9.1. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with IMVT
Add Immunovant, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with IMVT